Communiqués Ligand Pharmaceuticals Incorporated

Actions

LGND

US53220K5048

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
283,49 ^USD	-0,43%		-0,34%	+49,94%

09/09	Ligand Pharmaceuticals : un dirigeant cède des actions pour un montant de 1 430 434 $, selon un récent document de la SEC	MT
07/08	Ligand Pharmaceuticals Incorporated : RBC Capital Markets maintient sa recommandation à l'achat	ZM

Communiqués

26/08	Ligand to Participate in September Investor Conferences	AQ
06/08	Ligand: Q2 Earnings Snapshot	AQ
06/08	Ligand Reports Second Quarter 2026 Financial Results	AQ
23/07	Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026	AQ
14/07	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets	GL
14/07	XOMA Royalty Announces Closing of Its Acquisition by Ligand	AQ
14/07	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets	AQ
30/06	Zerion Pharma completes royalty financing and equity investment transaction with Ligand to advance the Dispersome® technology	AQ
25/06	Ligand Announces Closing of Convertible Senior Notes Offering	AQ
23/06	Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering	AQ
22/06	Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031	AQ
10/06	Ligand Announces 2026 Investor Day in New York City	AQ
27/05	Ligand to Participate in June Investor Conferences	AQ
07/05	Ligand Pharmaceuticals Incorporated : First Quarter 2026 Earnings Webcast	PU
07/05	Ligand: Q1 Earnings Snapshot	AQ
07/05	Ligand Reports First Quarter 2026 Financial Results	AQ
05/05	Ligand to Participate in May Investor Conferences	AQ
27/04	Ligand Pharmaceuticals Incorporated : To Acquire XOMA Royalty	PU
27/04	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	AQ
22/04	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026	AQ
15/04	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI in FSGS	AQ
26/03	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team	AQ
04/03	Ligand to Participate in March Investor Conferences	AQ
26/02	Ligand: Q4 Earnings Snapshot	AQ
26/02	Ligand Pharmaceuticals Incorporated : Fourth Quarter 2025 Earnings Webcast	PU